The event will take place in the morning in the European Parliament as a breakfast roundtable. If you are unable to attend but know of someone who would like to attend, please let me know.
This event is organized in partnership with Abbvie and will bring together prominent stakeholders from EU institutions, patients’ voices, and industry, to discuss how to develop the most effective framework for inclusive and forward-looking pharmaceutical legislation.
Migraine carries an annual economic burden of €27 billion and is one of the leading causes of disability. Despite the tangible unmet need, it is not consistently recognised as a medical burden, especially when it comes to preventative treatment. Migraine might not be deadly, but it is debilitating.
Current policy proposals may offer an opportunity to address the challenges, but a risk remains in the newly proposed unmet medical need definition. As it stands, the definition may see migraine get deprioritised as recognition of the existing unmet need is brought into question.
How do we ensure that these approaches are well-defined and open the door to medical advances that leave no patient behind?
During the event part of the discussion would centre around the following points
· How does the inconsistent recognition of migraine as a medical burden affect preventative treatment options and patient care?
· What should be considered in the definition of unmet medical need to ensure patients suffering from migraine do not miss out following the revision of pharmaceutical legislation?
· While Brussels’ renewed commitment to mental health is welcome, what more can the European Union do on a policy level to drive forward the commitments specific to brain health?